EP1406658A1 - Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan - Google Patents
Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitanInfo
- Publication number
- EP1406658A1 EP1406658A1 EP02751038A EP02751038A EP1406658A1 EP 1406658 A1 EP1406658 A1 EP 1406658A1 EP 02751038 A EP02751038 A EP 02751038A EP 02751038 A EP02751038 A EP 02751038A EP 1406658 A1 EP1406658 A1 EP 1406658A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cetuximab
- solution
- polyoxyethylene
- liquid pharmaceutical
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates to a stable liquid pharmaceutical formulation comprising the chimeric monoclonal antibody C225 (cetuximab ®) against the receptor of epidermal growth factor
- Cetuximab ® is a promising antibody that binds to the EGF receptor. Cetuximab ® and C225 is recombined different species from the DNA, and was first described by Naramura et al. (Cancer Immunol Immunotherapy 37, 343-349, 1993). With regard to the production of Cetuximab ® referenced called scientific literature.
- Cetuximab ® is administered parenterally as a solution for therapeutic use.
- a particular problem with antibody solutions is their tendency to aggregate and form protein multimers. In the case of reducible multimers, this may be due to unintended intermolecular disulfide bridge formation through an interaction between approaching moieties. Also suitable are hydrophobic interactions and the associated formation of non-reducible multimers. Furthermore, there are deamidation reactions, which subsequently lead to protein degradation reactions. As a result of the mentioned tendency to aggregation, product precipitations occur during storage of antibody solutions, so that a reproducible removal from the container containing the solution is called into question. In addition, parenteral administration of particle-containing solution can lead to embolisms. As a result, a reproducible
- a common method for stabilizing monoclonal antibodies is the freeze-drying of solutions containing antibodies as well as excipients.
- lyophilization is very time and energy consuming and therefore expensive.
- the lyophilisate must first be reconstituted before administration.
- EP 0 073 371 describes intravenously administrable compositions containing immunoglobulins which have a pH of from 3.5 to 5.0 for stabilization. However, such low pH values lead to undesirable incompatibility reactions at the injection site.
- US 6,171,586 B1 discloses the use of an acetate buffer pH 4.48 to 5.5, a surfactant and a polyol in a liquid formulation of antibodies, excluding NaCl for isotonization. Due to the low pH value as well as the lack of isotonization, incompatibility reactions at the injection site can also occur.
- EP 0 280 358, EP 0 170 983 and US Pat. No. 5,945,098 may be mentioned at this point.
- EP 0 280 358 describes the addition of dextran to a
- Antibody solution for stabilization against certain hormones achieving stability over nine months.
- EP 0 170 983 describes the stabilization of a thermolabile monoclonal antibody by heating together with hydrolyzed
- Ovalbumin whereby the antibody after 7 days of storage at 45 ° C was still stable.
- the addition of proteins of other species to administrable formulations intended for parenteral administration is undesirable because of the problems involved, in particular their possible antigenicity.
- US 5,945,098 discloses the use of glycine, polysorbate 80 and polyethylene glycol to stabilize a liquid formulation of immunoglobulin G.
- cetuximab ® suitable for parenteral administration, fluid formulation that is well tolerated and when stored at room temperature over a year is at least stable.
- the formulation should have a simple structure and contain no toxicologically harmful excipients.
- cetuximab ® contains a phosphate buffer in the range of approximately pH 6 to approximately pH 8 and a polyoxyethylene sorbitan fatty acid ester.
- the subject of the present invention is therefore a stable liquid pharmaceutical composition containing a phosphate buffer in the range of pH 6 to pH 8 and a polyoxyethylene sorbitan fatty acid ester.
- the pH is in the range of 6.5 to 7.5, more preferably a pH of about 7.2.
- Suitable phosphate buffers are solutions of mono- and / or di-
- phosphate buffer can in the formulation of the invention in a
- Concentration range from 2 mM to 100 mM. Preferred is a concentration range of 5 mM to 20 mM, more preferably about 10 mM.
- Cetuximab ® can in the formulation of the invention in a
- 2 mg / ml to 10 mg / ml, more preferably about 5 mg / ml are included.
- polyethylene sorbitan fatty acid esters are also known under the trademark Tween.
- Polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, and polyoxyethylene (20) sorbitan monostearate are particularly useful in the formulation of this invention.
- Polyoxyethylene (20) sorbitan monolaurate and polyoxyethylene (20) sorbitan monooleate are preferred, of which polyoxyethylene (20) sorbitan monooleate is particularly preferred.
- Polyethylene sorbitan fatty acid esters may be included in the formulation in a concentration of 0.001% to 1.0%. Preferably, 0.005% to 0.1%, more preferably about 0.01% are included.
- the formulation according to the invention additionally contains a
- Isotonizing agent preferably a physiologically acceptable salt, such as sodium chloride or potassium chloride, or a physiological compatible polyol, such as glucose or glycerol, in a concentration required for isotonization.
- the invention is therefore a liquid formulation comprising Cetuximab ®, a phosphate buffer in the range of approximately pH 6 to approximately pH 8, a polyoxyethylene sorbitan fatty acid ester and an isotonizing agent in a concentration necessary for establishing isotonicity.
- the formulation contains sodium chloride as an isotonizing agent.
- the liquid formulation of approximately 5mg / ml Cetuximab ® contains about 10 mM
- Phosphate buffer with a pH of about 7.2, about 145 mM sodium chloride and about 0.01% polyoxyethylene (20) sorbitan monooleate Phosphate buffer with a pH of about 7.2, about 145 mM sodium chloride and about 0.01% polyoxyethylene (20) sorbitan monooleate.
- the formulation of the invention can be prepared by a cetuximab ® solution containing the ingredients listed are added. Conveniently, this is a solution with a defined concentration of cetuximab ®, as it is obtained in its preparation, mixed with defined volumes of stock solutions containing the said further ingredients in defined concentration and and optionally diluted with water to the pre-calculated concentration. Alternatively, the ingredients of the cetuximab ® containing feed solution may also be added as solids. Is cetuximab ® as a solid, for example as a lyophilisate, the formulation of the invention can be prepared by cetuximab ® one or more of the further first in water or an
- one or more of the ingredients contained in the inventive formulation are already during or added at the end of the manufacturing process of cetuximab ®.
- this can be done by using Cetuximab ®, several or all further ingredients containing aqueous solution is dissolved in the last step of carried out after its preparation purification directly in a one.
- the respective further ingredient (s) need only be added in a lesser amount and / or not at all to prepare the formulation. It is particularly preferred if, in the last step of the purification carried out after its preparation, the particular ingredient is dissolved directly in an aqueous solution containing all further ingredients, so that the formulation according to the invention is obtained directly.
- the preparation was carried out by mixing defined volumes of the respective ingredients in a defined concentration containing aqueous
- Solution A drug solution containing:
- Solution B (buffer / salt solution): corresponds to solution A, but contains no active ingredient.
- Solution C polyoxyethylene sorbitan fatty acid ester solution: corresponds to solution B, but additionally contains 1% by weight of polyoxyethylene (20) sorbitan monooleate.
- the prepared solution was filtered with a sterile filter before filling.
- the vials were filled with a pipette with 2 ml solution each.
- Example 2 (comparative formulation) Aqueous solution containing:
- Example 3 To prepare the comparative formulation, 10 ml each of the solutions A and B described in Example 1 were combined with each other.
- the preparation was carried out by mixing defined volumes of the respective ingredients in a defined concentration containing aqueous solutions.
- the following solutions were used:
- Solution B polyoxyethylene sorbitan fatty acid ester glucose solution
- Example 1 and for comparison purposes vials containing solution according to Example 2 stored at 40 ° C and 75% relative humidity. Prior to storage and after defined storage periods, 3 vials were assessed visually by direct irradiation with a cold light source and the absorption of the solutions at 350 and 550 nm was determined, which represents a measure of the turbidity. Furthermore, 3 vials were each removed and analyzed for the content of cetuximab ® and decomposition products by HPLC-gel filtration examined.
- phosphate buffer pH 7.2 was used as a flow agent.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10133394A DE10133394A1 (en) | 2001-07-13 | 2001-07-13 | Liquid formulation containing cetuximab |
DE10133394 | 2001-07-13 | ||
PCT/EP2002/006696 WO2003007988A1 (en) | 2001-07-13 | 2002-06-18 | Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1406658A1 true EP1406658A1 (en) | 2004-04-14 |
Family
ID=7691220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02751038A Withdrawn EP1406658A1 (en) | 2001-07-13 | 2002-06-18 | Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
Country Status (18)
Country | Link |
---|---|
US (1) | US20040170632A1 (en) |
EP (1) | EP1406658A1 (en) |
JP (1) | JP2004536129A (en) |
KR (1) | KR20040018458A (en) |
CN (1) | CN1231264C (en) |
AR (1) | AR039358A1 (en) |
BR (1) | BR0211060A (en) |
CA (1) | CA2453342A1 (en) |
CZ (1) | CZ2004189A3 (en) |
DE (1) | DE10133394A1 (en) |
HU (1) | HUP0401046A3 (en) |
MX (1) | MXPA04000340A (en) |
PE (1) | PE20030433A1 (en) |
PL (1) | PL364599A1 (en) |
RU (1) | RU2004102395A (en) |
SK (1) | SK862004A3 (en) |
WO (1) | WO2003007988A1 (en) |
ZA (1) | ZA200401161B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3777880A1 (en) | 2003-02-10 | 2021-02-17 | Biogen MA Inc. | Immunoglobulin formulation and method of preparation thereof |
DE10355251A1 (en) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Water-based pharmaceutical preparation for treatment of tumors has active ingredient effective against receptor of endothelial growth factor receptor |
DE10355904A1 (en) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Solid forms of anti-EGFR antibodies |
CN1953768B (en) * | 2004-02-12 | 2010-10-13 | 默克专利有限公司 | Highly concentrated liquid formulations of anti-EGFR antibodies |
RU2408387C2 (en) * | 2004-04-27 | 2011-01-10 | Веллстат Байолоджикс Корпорейшн | Virus and camptothecin based treatment of malignant growth |
JP2008519757A (en) * | 2004-11-12 | 2008-06-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Anti-EGFR antibody solid |
ME01222B (en) * | 2005-02-28 | 2013-06-20 | Eisai R&D Man Co Ltd | Novel combinational use of a sulfonamide compound in the treatment of cancer |
CA2642665C (en) | 2006-02-09 | 2013-01-08 | Daiichi Sankyo Company, Limited | Anti-cancer pharmaceutical composition |
CA2650953A1 (en) | 2006-05-03 | 2007-11-15 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
WO2008045373A2 (en) * | 2006-10-06 | 2008-04-17 | Amgen Inc. | Stable antibody formulations |
MX2009003982A (en) * | 2006-10-20 | 2009-04-27 | Amgen Inc | Stable polypeptide formulations. |
CN107773755B (en) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | Injection preparation of anti-epidermal growth factor receptor monoclonal antibody |
EP3624846A1 (en) | 2017-05-16 | 2020-03-25 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
EP3811962A4 (en) * | 2018-06-25 | 2022-03-16 | JCR Pharmaceuticals Co., Ltd. | Protein-containing aqueous liquid formulation |
US20210290644A1 (en) * | 2018-08-31 | 2021-09-23 | Amplyx Pharmaceuticals, Inc. | Compounds and methods for treating fungal infections |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
WO1996040210A1 (en) * | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
CN102416176A (en) * | 1995-07-27 | 2012-04-18 | 基因技术股份有限公司 | Stabile isotonic lyophilized protein formulation |
-
2001
- 2001-07-13 DE DE10133394A patent/DE10133394A1/en not_active Withdrawn
-
2002
- 2002-06-18 HU HU0401046A patent/HUP0401046A3/en unknown
- 2002-06-18 EP EP02751038A patent/EP1406658A1/en not_active Withdrawn
- 2002-06-18 WO PCT/EP2002/006696 patent/WO2003007988A1/en not_active Application Discontinuation
- 2002-06-18 CN CNB028141059A patent/CN1231264C/en not_active Expired - Fee Related
- 2002-06-18 CA CA002453342A patent/CA2453342A1/en not_active Abandoned
- 2002-06-18 SK SK86-2004A patent/SK862004A3/en not_active Application Discontinuation
- 2002-06-18 PL PL02364599A patent/PL364599A1/en unknown
- 2002-06-18 RU RU2004102395/15A patent/RU2004102395A/en not_active Application Discontinuation
- 2002-06-18 CZ CZ2004189A patent/CZ2004189A3/en unknown
- 2002-06-18 JP JP2003513593A patent/JP2004536129A/en not_active Withdrawn
- 2002-06-18 KR KR10-2004-7000530A patent/KR20040018458A/en not_active Application Discontinuation
- 2002-06-18 BR BR0211060-1A patent/BR0211060A/en not_active IP Right Cessation
- 2002-06-18 US US10/483,404 patent/US20040170632A1/en not_active Abandoned
- 2002-06-18 MX MXPA04000340A patent/MXPA04000340A/en unknown
- 2002-07-11 PE PE2002000618A patent/PE20030433A1/en not_active Application Discontinuation
- 2002-07-12 AR ARP020102605A patent/AR039358A1/en unknown
-
2004
- 2004-02-12 ZA ZA200401161A patent/ZA200401161B/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO03007988A1 * |
Also Published As
Publication number | Publication date |
---|---|
DE10133394A1 (en) | 2003-01-30 |
HUP0401046A2 (en) | 2006-04-28 |
CN1231264C (en) | 2005-12-14 |
US20040170632A1 (en) | 2004-09-02 |
CN1527724A (en) | 2004-09-08 |
PL364599A1 (en) | 2004-12-13 |
HUP0401046A3 (en) | 2006-11-28 |
RU2004102395A (en) | 2005-05-27 |
JP2004536129A (en) | 2004-12-02 |
CZ2004189A3 (en) | 2004-05-12 |
BR0211060A (en) | 2004-07-20 |
PE20030433A1 (en) | 2003-05-24 |
CA2453342A1 (en) | 2003-01-30 |
WO2003007988A1 (en) | 2003-01-30 |
KR20040018458A (en) | 2004-03-03 |
ZA200401161B (en) | 2004-10-22 |
SK862004A3 (en) | 2004-07-07 |
MXPA04000340A (en) | 2004-05-04 |
AR039358A1 (en) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1687031B1 (en) | Pharmaceutical preparation containing an antibody for the epidermal growth factor (egf) receptor | |
EP1455824B1 (en) | Lyophilized preparation containing antibodies to the egf receptor | |
DE69519300T2 (en) | STABLE MEDICINAL PRODUCT CONTAINING OXALIPLATINE | |
DE68908175T2 (en) | FREEZE DRIED FORMULATION FOR ANTIBODY PRODUCTS. | |
DE69218241T2 (en) | MEDICINE FORMULATION FOR PARENTERAL USE | |
DE4344824C1 (en) | Highly concentrated immunoglobulin preparation and process for its preparation | |
DE69621942T2 (en) | IMPROVED MANUFACTURING METHOD AND COMPOSITION FOR THERAPEUTIC CISPLATIN (CDDP) | |
DE3686221T2 (en) | EMULSIONS FOR PARENTERAL AND / OR ORAL ADMINISTRATION OF HEAVY WATER-SOLUBLE IONIZABLE HYDROPHOBIC MEDICINAL SUBSTANCES. | |
DE3752194T2 (en) | Fluorocarbons as a blood substitute | |
WO2003007988A1 (en) | Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan | |
DE69133042T2 (en) | LYOPHILIZED PREPARATION AND THEIR PRODUCTION | |
DE69213836T2 (en) | Megestrol acetate formulation | |
CH642852A5 (en) | MATERIAL SUITABLE FOR MARKING WITH A RADIONUCLIDE, METHOD FOR THE PRODUCTION AND USE THEREOF. | |
DE69827357T2 (en) | Human growth hormone containing pharmaceutical composition | |
DE2827027B2 (en) | Freeze-dried native T -globulin preparation for intravenous administration | |
DE10204792A1 (en) | Lyophilized preparation containing immunocytokines | |
DE3115080A1 (en) | MEDICINAL PRODUCTS FOR ORAL ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF | |
DE60101979T2 (en) | Solution containing N- [O- (p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and drug containing this solution | |
DE69428967T2 (en) | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | |
EP3099330B1 (en) | Stable alcoholic solution of alprostadil | |
DE69520231T2 (en) | LIPOSOME PREPARATIONS CONTAINING HYBRID INTERFERON | |
DE3877015T2 (en) | ANTIBODY-CONTAINING STABILIZED AQUEOUS COMPOSITION. | |
DE60005188T2 (en) | GRF-CONTAINING LYOPHILIZED COMPOSITIONS | |
DE2401453A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN PROLIFERATIONAL DISEASES | |
EP0108248B1 (en) | Aqueous nitroglycerine solution free of solubilizers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031127 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BACHMANN, CHRISTIANE Inventor name: HAAS, UDO Inventor name: MARTINI-MARR, ULRIKE Inventor name: MUELLER, ROBERT Inventor name: MAHLER, HANNS-CHRISTIAN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051229 |